ArticleWorld journal of gastroenterology2007
A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon.
Article in World journal of gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 84 citations in OpenAlex.
- Effect of microencapsulated sodium butyrate on abdominal symptoms and carbohydrate metabolism in patients with type 2 diabetes: a randomized placebo-controlled trial.Scientific reports · 2026Trial
- Trial
- Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis.World journal of gastroenterology · 2015Trial
- Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis--a prospective randomized study.International journal of colorectal disease · 2014Trial
- Gut Microbiota-Derived Short-Chain Fatty Acids in Inflammatory Bowel Disease: Mechanistic Insights into Gut Inflammation, Barrier Function, and Therapeutic Potential.International journal of molecular sciences · 2026Review
- Gut Microbiota in the Hepato-Cardiorenal Axis: Microbial Metabolites, Inflammation, and Emerging Therapeutic Targets.Current pharmaceutical design · 2026Review
- Dietary Supplementation with Encapsulated or Non-Encapsulated Sodium Butyrate Enhances Growth, Antioxidant Defense, Immunity, and Gut Health in Largemouth Bass (Microorganisms · 2025Article
- Update on antimicrobial peptides: key elements inThe Journal of general virology · 2025Review
- Beyond the Gut: Unveiling Butyrate's Global Health Impact Through Gut Health and Dysbiosis-Related Conditions: A Narrative Review.Nutrients · 2025Review
- A critical review of microbiome-derived metabolic functions and translational research in liver diseases.Frontiers in cellular and infection microbiology · 2025Review
- Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches.Pharmacology & therapeutics · 2024Review
- Butyric acid and prospects for creation of new medicines based on its derivatives: a literature review.Journal of veterinary science · 2024Review
- Uncovering a novel mechanism: Butyrate induces estrogen receptor alpha activation independent of estrogen stimulation in MCF-7 breast cancer cells.Genetics and molecular biology · 2024Article
- Film Coatings Based on Aqueous Shellac Ammonium Salt "SwanlacAAPS PharmSciTech · 2023Article
- Butyrate to combat obesity and obesity-associated metabolic disorders: Current status and future implications for therapeutic use.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2022Review
- Dietary supplements for intestinal inflammation.Journal of preventive medicine and hygiene · 2022Review
- Protective role of butyrate in obesity and diabetes: New insights.Frontiers in nutrition · 2022Review
- A Synbiotic Formulation ComprisingNutrients · 2021Article
- Microbiome therapeutics for hepatic encephalopathy.Journal of hepatology · 2021Review
- Reduction of gut microbial diversity and short chain fatty acids in BALB/c mice exposure to microcystin-LR.Ecotoxicology (London, England) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo develop a new formulation with hydroxy propyl methyl cellulose and Shellac coating for extended and selective delivery of butyrate in the ileo-caecal region and colon.
methodsOne-gram sodium butyrate coated tablets containing 13C-butyrate were orally administered to 12 healthy subjects and 12 Crohn's disease patients and the rate of 13C-butyrate absorption was evaluated by 13CO2 breath test analysis for eight hours. Tauroursodeoxycholic acid (500 mg) was co-administered as a biomarker of oro-ileal transit time to determine also the site of release and absorption of butyrate by the time of its serum maximum concentration.
resultsThe coated formulation delayed the 13C-butyrate release by 2-3 h with respect to the uncoated tablets. Sodium butyrate was delivered in the intestine of all subjects and a more variable transit time was found in Crohn's disease patients than in healthy subjects. The variability of the peak 13CO2 in the kinetic release of butyrate was explained by the inter-subject variability in transit time. However, the coating chosen ensured an efficient release of the active compound even in patients with a short transit time.
conclusionSimultaneous evaluation of breath 13CO2 and tauroursodeoxycholic acid concentration-time curves has shown that the new oral formulation consistently releases sodium butyrate in the ileo-cecal region and colon both in healthy subjects and Crohn's disease patients with variable intestinal transit time. This formulation may be of therapeutic value in inflammatory bowel disease patients due to the appropriate release of the active compound.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.